Nano Dimension Ltd., a leader in the field of 3D printed electronics, has supplied, in return for payment, its flagship DragonFly 2020 electronics 3D Printer to Syqe Medical Ltd. Syqe is the Tel Aviv-based developer of the world’s first selective-dose, pharmaceutical grade medical cannabis inhaler.
It uses 3D printers to prototype and produce inhalers, which have been used in Israel’s Rambam Hospital for more than a year. Syqe Medical joins the growing ranks of Nano Dimension’s beta clients, and plans to use Nano Dimension’s technology to further develop its inhalers.
Nano Dimension’s beta program involves the delivery of the company’s DragonFly 2020 3D Printers to leading companies and partners worldwide through a leasing model. These customers are pioneering additive manufacturing technology and techniques for electronics and circuitry, and are active in a variety of industries, including: defense, consumer goods, technology for the finance industry and medical devices.
The customers will qualify the DragonFly 2020 technology and will use it to speed up their product development cycles. The DragonFly 2020 3D printer also allows them to strengthen their in-house innovation capabilities, while providing them with enhanced R&D IP security. In return, companies make payments on their leases and provide Nano Dimension with valuable feedback for further product development.
Nano Dimension, founded in 2012, focuses on development of advanced 3D printed electronics systems and advanced additive manufacturing. Nano Dimension’s unique products combine three advanced technologies: 3D inkjet, 3D software and nanomaterials.
The company’s primary products include the first 3D printer dedicated to printing multi-layer PCBs (printed circuit boards) and advanced nanotechnology-based conductive and dielectric inks. The company’s American Depositary Shares are traded on the NASDAQ, and its ordinary shares are also traded on the TASE in Israel. The Bank of New York Mellon serves as the depositary for Nano Dimension.
Syqe Medical is transforming cannabis and other plants into standard prescription medicines. The first plant the company enabled for use in its inhaler is medical cannabis. Syqe was founded in 2011. In 2013 Prof. Elon Eisenberg conducted the company’s first clinical trial at Rambam Healthcare Campus, in Haifa, which demonstrated the inhaler’s precision and compliance with pharmaceutical standards. In 2016, Syqe announced it had signed an agreement with Teva Pharmaceutical Industries Ltd., the world’s largest manufacturer of generic drugs, to market and distribute Syqe inhalers in Israel.